These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 20526556

  • 1. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K, Amoh Y, Mii S, Eto H, Iwamura M, Katsuoka K.
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract] [Full Text] [Related]

  • 2. Erythema multiforme induced by sorafenib.
    Feltes RA, Feito Rodríguez M, González-Beato MJ.
    Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
    [No Abstract] [Full Text] [Related]

  • 3. Chloracne-like drug eruption associated with sorafenib.
    Pickert A, Hughes M, Wells M.
    J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
    [Abstract] [Full Text] [Related]

  • 4. Hand-foot and stump syndrome to sorafenib.
    Lai SE, Kuzel T, Lacouture ME.
    J Clin Oncol; 2007 Jan 20; 25(3):341-3. PubMed ID: 17235051
    [No Abstract] [Full Text] [Related]

  • 5. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC, Chaudhary UB.
    Oncologist; 2007 Oct 20; 12(10):1178-82. PubMed ID: 17962611
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib: atypical cutaneous side effects.
    Richetta AG, Maiani E, Carboni V, Carlomagno V, Cimillo M, Mattozzi C, Calvieri S.
    Eur J Dermatol; 2007 Oct 20; 17(6):549-50. PubMed ID: 17951148
    [No Abstract] [Full Text] [Related]

  • 7. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C.
    Arch Dermatol; 2008 Jun 20; 144(6):820-2. PubMed ID: 18559790
    [No Abstract] [Full Text] [Related]

  • 8. Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
    Sahai S, Swick BL.
    Int J Dermatol; 2010 Oct 20; 49(10):1203-6. PubMed ID: 20883411
    [Abstract] [Full Text] [Related]

  • 9. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul 20; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P.
    Cutan Ocul Toxicol; 2009 Jul 20; 28(2):90-2. PubMed ID: 19514932
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
    Kamada P, Dudek AZ.
    Cancer Invest; 2010 Jun 20; 28(5):501-4. PubMed ID: 20014944
    [Abstract] [Full Text] [Related]

  • 12. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M, Fujita T, Mii S, Tanabe K, Tabata K, Matsumoto K, Satoh T, Iwamura M.
    Jpn J Clin Oncol; 2012 Sep 20; 42(9):820-4. PubMed ID: 22782962
    [Abstract] [Full Text] [Related]

  • 13. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M, Ishida-Yamamoto A, Komatsu S, Iiduka H.
    J Dermatol; 2010 Sep 20; 37(9):833-4. PubMed ID: 20883372
    [No Abstract] [Full Text] [Related]

  • 14. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML, Chon SY.
    J Drugs Dermatol; 2010 Feb 20; 9(2):169-71. PubMed ID: 20214183
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS, Kung EF, Petronic-Rosic V, Sethi A.
    J Drugs Dermatol; 2008 Sep 20; 7(9):891-3. PubMed ID: 19112807
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS, Manchen B.
    Clin J Oncol Nurs; 2007 Oct 20; 11(5):649-56. PubMed ID: 17962173
    [Abstract] [Full Text] [Related]

  • 17. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ, Kish LS, Jaworsky C.
    J Am Acad Dermatol; 2009 Sep 20; 61(3):522-7. PubMed ID: 19700018
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.
    Oncology; 2010 Sep 20; 78(5-6):340-7. PubMed ID: 20733337
    [Abstract] [Full Text] [Related]

  • 19. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Xie XD, Piao Y, Liu ZZ.
    Zhonghua Zhong Liu Za Zhi; 2009 Sep 20; 31(9):714-5. PubMed ID: 20021872
    [No Abstract] [Full Text] [Related]

  • 20. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.
    Br J Dermatol; 2008 Mar 20; 158(3):592-6. PubMed ID: 18070211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.